Achieve Life Sciences, Inc. (NASDAQ:ACHV) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) have earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $15.50.

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a research report on Monday, December 29th. Citizens Jmp began coverage on shares of Achieve Life Sciences in a report on Tuesday, November 25th. They set a “market outperform” rating and a $19.00 price target on the stock. Raymond James Financial reiterated a “strong-buy” rating on shares of Achieve Life Sciences in a research note on Monday, November 24th. Finally, Citigroup began coverage on shares of Achieve Life Sciences in a research report on Tuesday, November 25th. They set an “outperform” rating on the stock.

Institutional Trading of Achieve Life Sciences

Several large investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new position in Achieve Life Sciences in the first quarter valued at about $32,000. Next Capital Management LLC purchased a new stake in shares of Achieve Life Sciences during the 3rd quarter valued at about $51,000. Sender Co & Partners Inc. purchased a new stake in shares of Achieve Life Sciences during the 2nd quarter valued at about $56,000. OneDigital Investment Advisors LLC bought a new position in shares of Achieve Life Sciences in the 3rd quarter worth approximately $63,000. Finally, Magnolia Capital Advisors LLC purchased a new position in shares of Achieve Life Sciences in the fourth quarter worth approximately $64,000. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Stock Performance

ACHV stock opened at $4.58 on Thursday. The stock’s 50 day simple moving average is $4.75 and its 200 day simple moving average is $4.18. The company has a current ratio of 5.14, a quick ratio of 5.14 and a debt-to-equity ratio of 0.26. Achieve Life Sciences has a 12-month low of $1.84 and a 12-month high of $6.03. The stock has a market capitalization of $243.79 million, a PE ratio of -3.32 and a beta of 1.81.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.